The National Cancer Institute (NCI)’s RAS initiative has been working with the Office of Cancer Clinical Proteomics Research (OCCPR) to launch a proteomic assay development and characterization project targeting RAS-associated pathways. The goal of this research, which aligns with one of NCI-OCCPR’s missions of providing publicly accessible, well-characterized reagents and resources for the cancer research community, is to develop, validate, and distribute monoclonal antibodies. These antibodies will enable the enrichment and detection of proteins and post-translational modifications involved in RAS signal transduction. Precision Antibody™ developed the antibody described in this manuscript.
To read the full Nature article, please download here.
Led by innovative minds in immunology and the antibody development field, Precision Antibody has been an industry leader for over 20 years. We not only implement a cutting-edge technique in antigen design, antibody development, production, and other analyses, but we are also constantly working on ways to improve and advance technology to match the ever-changing world of science. If you are interested in learning more about Precision Antibody’s Custom Antibody development.
Precision Antibody™ is the forefront of the global Custom Antibody industry & it is led by the innovative minds in immunology and antibody development field.
